Financial costs incurred because of breast cancer and the effects of such costs on the family financial situation may constitute an important adverse consequence of this disease. Even though Canadian breast cancer patients do not pay out of pocket for doctor visits or surgical and adjuvant treatments received in hospital because of publicly provided health care, they can still experience costs stemming from transportation to treatments and follow-up visits, accommodation, purchase of a prosthesis, consultations with different practitioners such as physiotherapists, and domestic help. Such costs are likely to affect an important proportion of women because breast cancer is now managed using multiple treatment modalities (1) (2) (3) , which results in a lengthy treatment course, frequent clinic visits, and a number of different side effects.
However, our understanding of the extent of out-of-pocket costs that result from breast cancer treatment remains incomplete, and only a few studies have empirically documented certain out-of-pocket costs for women with breast cancer (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) . These studies did not assess the full range of common out-of-pocket costs (6, 7, 12) or estimated costs only for specific treatments or short periods (5, (7) (8) (9) (10) (11) 13) . To our knowledge, no study has presented extensive information on the key out-of-pocket costs for women and their spouses incurred as a result of breast cancer for the entire first year after diagnosis for newly diagnosed early breast cancer. Our objectives were to 1) describe the extent of out-of-pocket costs among Canadian women and their spouses during the first year after diagnosis 2) identify women at risk of experiencing higher levels of out-of-pocket costs, and 3) describe effects of both out-of-pocket costs and wage losses on the family's financial situation during the same period.
Methods

Subjects
This prospective cohort study, which has been previously described (14) (15) (16) , was based on the consecutive series of women first treated for early breast cancer in 2003 in eight hospitals in several cities in the province of Quebec and, for women who were married or living with a partner, their spouses. Potentially eligible participants were identified through examination of operating lists for breast surgery or neoadjuvant chemotherapy and pathology reports. Women were ineligible if they were aged less than 18 years, had a previous history of breast cancer, other cancer, or distant metastasis at diagnosis, or were unable to participate in a telephone interview (no telephone, insufficient fluency in French, hearing problems, or other physical or psychological problems). Nuns were ineligible because they do not assume costs individually. A specially trained nurse explained the study objectives and procedures to all potentially eligible women.
Spouses were eligible if they were aged 18 years or older, living with the patient, and able to participate in a telephone interview. After being identified, the spouse was approached by the nurse at the hospital or by telephone after obtaining the woman's permission to do so. However, women not living with a spouse or whose spouse refused were still eligible.
All participants provided signed informed consent. Each participating hospital's ethics review committee approved the study.
Data Collection
We developed telephone interviews and related cost estimation algorithms for measuring costs that result from breast cancer for both the patient and a family member (17) . Interviews were conducted with the woman and the spouse separately at 1, 6, and 12 months after the start of the woman's treatment (either surgery or neoadjuvant chemotherapy). We defined out-of-pocket costs as all dollar amounts paid directly by the women and their spouses as a result of breast cancer and breast cancer treatment, excluding wage losses. In general, the 1-month interview focused on out-of-pocket costs related to surgery, the 6-month interview focused on outof-pocket costs related to adjuvant treatments, and the 12-month interview focused on out-of-pocket costs related to any late treatments (surgical or adjuvant) and on other types of costs. At the 1-month interview, we also collected information on the personal characteristics of the women and their spouses that might influence costs-namely, age at diagnosis, highest level of completed education, working status, family income in the year before diagnosis, and name of the center where first treated (to estimate distance from a woman's home). Detailed content of the interviews has been published (17) . Information on the women's medical characteristics (prognostic factors, surgeries performed, and adjuvant treatments received) was obtained through review of medical records.
All costs are presented in 2003 Canadian dollars [which can be converted to 2011 Canadian dollars, the most recent complete year at the time of publication, using the Bank of Canada conversion factor of 1.1688 (18); Canadian 2011 dollars can then be converted to American dollars (as of January 1, 2011) by multiplying by 1.0043].
Women's Out-of-Pocket Costs. For women, out-of-pocket costs assessed included costs associated with surgeries (breast, axillary, and reconstruction), adjuvant treatments (radiotherapy, chemotherapy, endocrine therapies, and targeted therapies), complications, and follow-up visits. These out-of-pocket costs were estimated by summing travel costs (transportation, parking, accommodation, and meals), costs for purchase of endocrine therapy, and purchases related to side effects (filgrastim, breast prosthesis, wigs). Out-of-pocket costs for consultations with different types of practitioners were also estimated as well as other costs (additional domestic help, clothing, vitamins and natural products).
To estimate transportation costs for those who travelled with their personal car, we used postal codes to calculate the distance [obtained from validated software (19) ] between the woman's residence and the treatment hospital. This distance was multiplied by $0.36 per kilometer, the 2003 rate for car travel by employees at the Université Laval, where the study was conducted. The resulting amount was multiplied by two to account for the return trip and then multiplied by the number of treatments received. For women who received radiotherapy, we also imputed costs for one pretreatment consultation with a radiotherapist and one visit for preparation of the radiotherapy site. For those who received chemotherapy, we imputed the cost of one preparatory visit with the hematologist or other oncology specialist responsible for this aspect of care.
We used taxi fares current in 2003 and distance travelled for those travelling by taxi. For respondents travelling by bus, rail, air, and ferry, we contacted the relevant companies to establish standard fares. Parking costs were estimated by multiplying the 2003 hospital parking rates at each hospital (some of which had special rates for cancer patients in treatment) by the number of treatments for respondents who reported having paid for parking. For those living away from home, we calculated accommodation costs by using the cost for accommodation reported by the respondent or imputed $25 per night for respondents who stayed with family or friends (2003 rate at the Université Laval). Meal costs were estimated using the number of meals reported by the respondent multiplied by 2003 meal reimbursement rates (at the Université Laval; breakfast = $8; lunch = $14; dinner = $23).
For endocrine therapy, we used the cost of one prescription reported by the woman multiplied by the number of prescriptions in the year after diagnosis. Costs related to side effects were obtained by summing all amounts reported by the woman for breast prosthesis, filgrastim, creams, bandages, skin lotion, wigs, scarves, hats, and hair lotions bought because of breast cancer.
Some women reported hospital/clinic visits for complications related to breast cancer. We imputed transportation costs for one return trip by car (95% used this means of transportation for surgery) at the location visited for the first complication and multiplied by the number of reported visits for complications. Travel costs for follow-up visits were estimated by assuming that each patient had one visit to receive pathology results and to discuss the treatment plan and two follow-up visits in the first year at the same hospital as breast surgery (20) . Thus, we calculated out-ofpocket costs for follow-up by multiplying cost estimates for breast surgery by three.
We also measured amounts paid for consultations with different types of practitioners for help coping with the disease or treatments. These practitioners included physiotherapists, dieticians, psychologists, massage therapists, chiropractors, acupuncturists, and homeopaths. Women were asked about the number of consultations they had had and whether they paid for them. Costs were then estimated by multiplying the number of consultations by an average rate for each type of care in Quebec in 2003 (21) . Although we asked about consultations with a psychiatrist, social worker, and occupational therapist, these were virtually always provided as part of hospital care and therefore resulted in no out-of-pocket cost.
We estimated extra out-of-pocket costs incurred because of breast cancer (ie, above what was experienced in the month before diagnosis) for indoor and outdoor household help, meal preparation, and child care during the acute treatment period (first 6 months after diagnosis). These additional weekly costs for household help attributable to breast cancer were calculated as the difference in such costs between the 6 months after diagnosis and the month before diagnosis for each type of help multiplied by the number of weeks the extra costs lasted.
Women were asked if they bought clothes because of breast cancer using a list that contained bra, swimsuit, blouse, sweater, skirt, pants, dressing gown, and nightwear. Cost was assessed by summing all the amounts reported for the items purchased. Outof-pocket costs for natural health products (vitamins and homeopathic products) used because of breast cancer were estimated from the cost of each product reported by the woman multiplied by the number of times purchased.
Spouse Out-of-Pocket Costs. We also estimated certain costs for spouses using similar procedures. Costs were estimated for transportation, meals, parking, and accommodation (where applicable) for accompanying or visiting the woman while she was in the hospital. If costs applied to the couple, such as when a woman and her spouse travelled together by car to and from treatments, costs were attributed to the woman only.
Financial Assistance Received. Total costs reported (either by treatment type or overall) are net costs because we considered any financial assistance received. In some instances, financial assistance received was already an integral part of the cost reported by the woman or the spouse. This was the case for the cancer lodge (which offers subsidized, low-cost accommodation and sometimes meals), special parking rates offered by some hospitals for frequent visitors, cost of a breast prosthesis that is partially reimbursed by a government program, and the costs of adjuvant endocrine therapy and filgrastim that are partially covered by private or government drug insurance. Women and spouses also sometimes reported amounts received from insurance, community organizations, or government programs as overall compensation for one specific type of treatment, and these amounts were deducted from treatment costs.
Indicators of Family Financial Situation. At the 1-month interview, we collected information on annual family income before taxes using pre-established categories. We also questioned women about their perceptions of the family's financial situation in the past 12 months using eight questions administered at both the 1-month and 12-month interviews. These questions were adapted from published studies and questionnaires (22) (23) (24) (25) (26) . Specifically, we asked about the woman's satisfaction with her family's financial situation and her worry about and perception of her family's financial situation compared with that of others of the same age. Perceptions of ability to meet regular expenses for food and housing, to pay bills, to purchase medications, and to deal with unforeseen expenses were also assessed.
Statistical Analyses
We used descriptive statistics to present estimated out-of-pocket costs for women, their spouses, and the couple. Women not receiving a specific type of treatment were not included in cost calculations for this type of treatment. We assigned $0 to any women who received a specific treatment but who did not experience costs related to it. We also describe, for each type of cost, its proportion of the total amounts spent by all participating women.
To identify women at risk of higher levels of out-of-pocket costs, defined as those in the highest quartile of total out-of-pocket costs (≥$1773), we computed prevalence ratios (PRs) and 95% confidence intervals (CIs) using a generalized linear model with a log link and a Poisson working model (27) . Model-robust variances were obtained with sandwich estimators to account for the larger variance of Poisson variables compared with binomial variables (28) . The influence of different characteristics (age at diagnosis, number of different types of adjuvant treatments undergone, distance between home and hospital where first treated [km], highest level of completed education, employment status at diagnosis, level of family income) on high levels of out-of-pocket costs was examined first in univariate models. We then built a multivariable model that included all characteristics. Characteristics least statistically significant were removed one by one from the multivariable model until all remaining characteristics were statistically significant at the 5% level. The median level of out-of-pocket costs was also described according to different levels of family income and tested for linear trend using the Jonckheere-Terpstra test (with the missing income category excluded from the linear contrast). A similar analysis was performed using the proportion of family income represented by out-of-pocket costs estimated using the midpoint of each of the 12 before-tax family income categories and $120 000 for the last category (>$100 000).
Effects of out-of-pocket costs on women's financial situation were assessed in relation to the percentages of women who reported a change for the worse in the family's financial situation during the year after diagnosis. Change for the worse was identified by comparing reported levels on the indicators of their family's financial situation for the 12 months before diagnosis to those reported 12 months after diagnosis. In this analysis, it was essential to consider both out-of-pocket costs and any wage losses from breast cancer [which we described in a previous paper for women working at diagnosis (14)]. We estimated wage losses as the annual before-tax wages that would have been earned had the women not been absent from work because of breast cancer. Wage loss estimates were calculated using information on weekly wages before diagnosis and duration of absence, minus any salary compensation received. The proportions of patients who had experienced a change for the worse in the indicators of family financial situation were compared using the four categories obtained from the combination of out-ofpocket costs categorized as low (three lowest quartiles, <$1773) or high (highest quartile, ≥$1773) and wage losses categorized as low (three lowest quartiles, <$5726) or high (highest quartile, ≥$5726). For these analyses, women not working at diagnosis were assigned $0 in terms of wage losses. Prevalence ratios and 95% confidence intervals were estimated using a generalized linear model with a log link and a Poisson working model, as described above (27, 28) , and adjusted for age (23-49, 50-59, and 60-88 years) and family income in the year before diagnosis ($0-$29 999, $30 000-$49 999, $50 000-$79 999, >$80 000).
The sample size was determined based on power considerations for adequately assessing relations between costs (in quartiles) and levels of psychological distress, another study objective and the one that required the highest number of subjects. All statistical tests were two-sided. All analyses were performed using SAS version 9.2 software (SAS Institute, Cary, NC).
results
Participants
During the study period, 1397 women with breast cancer were identified. Of the 962 patients who met eligibility criteria, 829 (86.2%) consented to participate and completed the 1-month interview, and 800 of the 962 initially eligible women (83.2%) completed all three interviews. Among these 800 women, 541 women had a cohabiting spouse, but eligibility could only be assessed for 482 spouses, and of these, 465 were considered eligible. Considered overall, 391 of 541 spouses (72.3%) consented to participate, and all 391 completed the three interviews.
At diagnosis, the majority of women were living with a spouse (67.8%), and 57.4% were working (Table 1) . Most (86.6%) had invasive breast cancer. All but one had breast surgery. The great majority had partial mastectomy (79.6%) and adjuvant radiotherapy (86.6%).
Extent of Out-of-Pocket Costs
The median total net out-of-pocket cost incurred by women during the year after diagnosis after taking any compensation received into account was $1002 (mean = $1365, SD = $1238) ( Table 2) , and the distribution of costs was highly skewed (Figure 1 ). The median out-of-pocket cost related to surgeries, adjuvant treatments, and follow-up was $716 (mean = $1015, SD = $950) ( Table 2 ). More specifically, median out-of-pocket costs were $22 (mean = $71, SD = $128) for breast surgery, $351 (mean = $505, SD = $496) for radiotherapy, and $453 (mean = $613, SD = $542) for chemotherapy. Travel costs (transportation, parking, accommodation, and meals) accounted for a high proportion of costs associated with radiotherapy (median = 98.7%), whereas for chemotherapy, a median of 57.4% of costs were associated with the management of side effects for this treatment (purchase of wig, filgrastim).
During the first year after diagnosis, 37.8% of women consulted other types of practitioners. Women paid a median of $128 (mean = $376, SD = $642) for these services. Consultations with a psychologist, massage therapist, and physiotherapist were those most frequently reported (42.1%, 35.8%, and 35.1%, respectively). Other types of costs-additional home/family help, clothing, and vitamins-were reported by 480 women, and the median cost was $150 (mean = $336, SD = $527). Out-of-pocket costs related to surgeries, adjuvant treatments, and follow-up represented 74.4% of the total dollar amount spent by this group of women, whereas costs for other practitioners and other types of costs represented 10.6% and 15.0%, respectively, of the total dollar amount spent (Figure 2) .
Overall, the median out-of-pocket cost for spouses was $111 (mean = $234, SD = $320), and this represented a median of 9% of the couple's total expenditures. The proportion of outof-pocket costs attributed to the spouse was highest for surgery (median = 63%) compared with other treatments (radiotherapy: median = 0%; chemotherapy: median = 8%) ( Table 3) .
Total out-of-pocket costs increased according to the level of family income. Women reporting family incomes of less than $30 000, $30 000-$49 999, $50 000-$79 999, and $80 000 or more spent a median of $687, $1061, $1004, and $1359, respectively (P value for linear trend [P trend ] < .0001). This trend was observed also for costs related to surgeries, adjuvant treatments, and follow-up (P trend = .0004), costs for consultations with other practitioners (P trend < .0001), and other types of costs (P trend = .002). Out-of-pocket costs represented a median of 2.3% of annual family income. However the median proportion spent was higher (4.3%) for families with incomes of less than $30 000, compared with 1.3% among women reporting incomes of $80 000 or more (P trend < .0001) ( Table 4) .
Characteristics That Influenced Out-of-Pocket Costs
In multivariable models, women who received two and three different types of adjuvant treatments were more likely to have outof-pocket costs in the highest quartile (≥$1773) than those who received no or only one type of adjuvant treatment (two treatments: PR = 1.56; three treatments: PR = 2.72; P trend < .0001) (Table 5) . Also, women who lived between 50.1 and 100 km and those who lived more than 100 km from the hospital where first treated were 2.89 and 4.03 times more likely, respectively, to have higher costs than those who lived 50 km or less away (P trend < .0001). Compared with women with a high school education or less, those with a collegial level or university diploma were more likely to experience costs in the highest quartile (P trend = .0001). Also, those women who were working at diagnosis were more likely to experience costs in the highest quartile (PR = 1.40, 95% CI = 1.07 to 1.84, P = .01) than those who were not working.
Effects on Family Financial Situation
The key variable negatively affecting perceptions of the family's financial situation was having higher wage losses. Using a reference group of women with both low out-of-pocket costs and low wage losses, prevalence ratios for a change for the worse in most indicators of family financial situation were statistically significantly higher (adjusted prevalence ratios ranging from 2.12 to 5.46) when women had high wage losses whether or not they had high out-ofpocket costs (Table 6 ). However, women with high out-of-pocket costs combined with low wage losses did not generally experience statistically significant increases in the risk of changes for the worse when compared with women with both low costs and low wage losses. It is important to note that relatively small numbers of women (≤8%) reported a change for the worse in their ability to pay for basics such food, lodging, or medications.
Discussion
Among these Canadian women who were receiving care that was consistent with current clinical guidelines for the treatment of early breast cancer (1) in a publicly funded health-care system, a median of $1002 (approximately $80 per month) and 2.3% of annual family income was spent on out-of-pocket costs for all expenditures incurred because of breast cancer during the first year after diagnosis after taking any financial assistance received into account. Out-of-pocket costs that were more directly related to receipt of treatments and management of their side effects accounted for three-quarters of the total costs experienced by the 800 participating women. Women who had more adjuvant treatments, lived further from the treatment center, had higher levels of education, and were working at diagnosis were all more likely to experience higher costs. Furthermore, with respect to changes for the worse in the women's perceptions of their family's financial situation, we found that women's out-of-pocket costs played a secondary role to wage losses; it is wage losses that appeared to drive changes for the worse.
Spouses' out-of-pocket costs were low, with a median of $111 for the entire year, and these costs represented a median of only 9% of the expenditures for participating couples. Spouses' sources of out-of-pocket costs were mainly limited to travel and related costs when accompanying the patient. Our calculation method may have contributed to low spousal costs because any costs such as parking that involved the couple members together were attributed to the woman only. Conceptually, this seemed reasonable based on our earlier focus group findings that costs experienced by the woman were unavoidable and also seen as family costs (29) .
To our knowledge, this study is the first to assess out-of-pocket costs associated with each of the main steps inherent in medical management of and recovery from early breast cancer during the first year after diagnosis and to do so for both the woman and her spouse. One study assessing similar costs that was conducted in the United States indicated that costs were US $137 and $174 per month among women 0 to 5 months after diagnosis and 6 to 12 months * The category "primary to high school" represents 11 to 12 years of schooling, and "collegial level" represents the 2 to 3 years after high school but before university-level education. † Among women receiving these types of treatment. ‡ Among radiotherapy, chemotherapy, and hormone therapy. (Table continues) after diagnosis, respectively (10) . One previous study reported on costs among 74 Canadian breast cancer patients and focussed on out-of-pocket costs for a 1-month period among women at different points in the treatment trajectory (13) . Estimates were Canadian $393 per month for costs such as drugs, domestic help, vitamins, and costs totaled $225 for transportation. However, because extent and types of costs may vary from one phase of the disease management to another (eg, the period of intensive treatments compared with the convalescent period or for care for early vs distant disease) it is difficult to be confident about extrapolating these time-specific estimates cumulatively to the entire year after diagnosis. The kinds of out-of-pocket costs we identified associated with the receipt of medical treatment and recovery are ones that likely affect women across Canada, the United States, and other countries, given that these out-of-pocket costs are generally not systematically covered by any health-care system or insurance company. Several observations contribute to confidence in the estimates of out-of-pocket costs we report here. First, this prospective study was based on the consecutive series of women diagnosed and treated in eight hospitals serving both urban and rural areas. Participation among eligible women and retention in the study were excellent (86% and 97%, respectively) and were good among spouses (72% and 100%, respectively). Second, the validity of cost estimates obtained using the estimation method we developed has been shown to be good (17) . During telephone interviews, respondents were not often asked to report dollar amounts spent. Most questions focused on facts, and it was the research team, not the respondent, who attributed a monetary value to these responses and combined different responses to obtain cost estimates. Producing estimates using information obtained directly from patients and spouses meant we were able to capture the variability that resulted from different treatment trajectories, availability of medical and financial resources, and patient preferences. Third, we also took reported financial assistance into account in our estimates, so costs reported reflect the out-of-pocket costs that women really had to pay. We have shown in previous analyses that incorporating financial aid received (eg, residence at a cancer lodge, special parking fares for those undergoing treatments) had an important effect on reducing out-of-pocket costs for accessing radiotherapy for some women (15) .
This study has some potential limitations. First, total outof-pocket costs reported here are still underestimated for some women. Although we measured costs related to two prescription drugs, endocrine therapy and filgrastim-and this latter can be very costly-we were unable to exhaustively cover costs that resulted from over-the-counter and other prescription drugs used because of breast cancer. We did attempt to measure such drugs, but within the constraints of an already long interview, we subsequently concluded that the information obtained was insufficient for making valid estimates. However, all residents in the province of Quebec have insurance that covers prescribed medications from either their employer or from the government. Second, in this 2003 cohort, only 5% of women received targeted therapy and incurred important costs because of the frequently required visits to the hospital. However in 2008, approximately 13% of women at our supraregional breast cancer center, and between 6% and 10% of women in other estimates (30) , were HER2/neu positive and thus likely to accumulate additional travel costs. Finally, spouse costs reported here may have been low as an artifact of attributing to the woman any costs incurred for transportation, parking, and accomodation when the spouse accompanied the woman. We also recognize that spouse costs cannot completely capture costs incurred by other members of the woman's family. Women may receive help for transportation from other family members, particularly if the spouse is working or elderly. Nonetheless, in the qualitative part of this study, caregivers of breast cancer patients said that their financial costs were not great (29) . The types of out-of-pocket costs documented here affect virtually all women with breast cancer to some degree. It is important to keep in mind that costs for treatments and follow-up represented three-quarters of total costs and are mostly unavoidable. We identified subgroups of women who experienced higher burden from these costs, including women with higher travel costs because of frequent trips for adjuvant treatments or longer distances to travel. Other determinants of higher costs were higher educational level and working at diagnosis, characteristics that likely reflect greater availability of financial resources and ability to pay. Even if costs were lower for women with lower family incomes, they are probably more burdensome in this group for two reasons. First, these women might reduce certain potential expenses for care and services that could improve quality of life but that can be considered avoidable and dependant on ability to pay (5) . Second, in our study and that of Arozullah et al. (10) , the proportion of family income represented by out-of-pocket costs was larger among women with lower family income compared with that among women with higher family income. This burden could be even greater in the lower income group in countries where patients must also pay out of pocket for medical and hospital visits and treatments.
Breast cancer-related wage losses, not out-of-pocket costs, made the most important contribution to women's perception of changes for the worse in the family's financial situation over the course of the first year after diagnosis. This is not surprising because we previously reported that during this same first year after diagnosis women who were working at diagnosis lost a substantial proportion-a mean of 27% or a median of 19%-of what they would have earned during that period had they not been absent because of breast cancer (14) . Some authors have characterized patients that have had a reduction of 20% or more in annual income because of cancer treatment as those who experience financial hardship (31) . Previous studies that have included wage losses and out-of-pocket costs indicate that wage losses represented a substantial proportion of the cancer patient's total costs (10, 12, 32) . This was also corroborated in our qualitative study in which some women indicated that wage losses were the most important financial cost of breast cancer (29) .
Our results-that out-of-pocket costs were relatively modest for some women, that they represented a relatively small proportion of family income, and that less than 10% of women reported changes for the worse after breast cancer in their ability to pay for basics like food, lodging, or medications-could be used by medical teams to reassure patients. For those groups of women we identified to be at risk of higher costs, information could be provided as women embark on the treatment trajectory to help them better plan for and manage these costs. Addressing this could be particularly important because at the time of diagnosis and the following weeks, the main focus of women and caregivers was survival, with little thought for possible financial consequences (29) . Initiatives to empower patients and families could include providing information about programs available to them and about tools to plan and track expenses, as such information may be important for later income tax returns and potential deductions for health-care expenses (33, 34) . Such initiatives should be encouraged because barriers to dealing with cost questions in the clinical setting include the absence of systematic approaches for assessing financial needs and the fact that patients may not be forthcoming with the healthcare team about financial concerns (31, 35) . Recent innovations in treatment for breast cancer may contribute to changing the level of costs for some patients and their family, but their overall impact on total costs is difficult to judge at this point. For example, recent results from randomized, controlled trials may lead to abbreviated radiation courses for some women (36) (37) (38) . Additionally, genomic testing, such as with the Oncotype DX (39), will help identify women who are unlikely to benefit from chemotherapy, thus reducing the number of women unnecessarily exposed to chemotherapy-related expenses. Still, such advances may be offset by other innovations in individualized medicine, such as the use of trastuzumab, which requires that women still make repeated visits to the clinic during treatment.
Lastly, it is important to realize that the cost estimates we presented already incorporate different types of financial assistance that are built into the cancer care system in which these women were treated. These include a substantial subsidy for the breast prosthesis, reduced accommodation rates when residing at a cancer lodge residence (and the inclusion of meals in some cases), special parking rates for patients in active treatment, and different government-, hospital-, or community-based programs that Table 6 . Prevalence of reporting a change for the worse in family financial situation over the year after diagnosis comparing women with different levels of out-of-pocket (OOP) costs and wage losses (N = 758)* provide financial assistance for travel for women who live considerable distances from the treatment center. Maintaining these programs and implementing new ones will play an important role in keeping cancer-related expenses down not only for breast cancer patients but probably also for patients facing other types of cancer.
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